Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder

Andrew W. Goddard, Anantha Shekhar, Aaron F. Whiteman, Christopher J. McDougle

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Obsessive-compulsive disorder (OCD) is a disabling psychiatric condition affecting 1-2% of the community. Although modern drug, behavioral and psychosurgical therapies have improved the prognosis of OCD considerably, approximately 30% of patients remain treatment-refractory. Currently, selective serotonin (5-HT) reuptake inhibitors (SSRIs) are the drug treatments of choice for OCD. Accordingly, this review evaluates the evidence for a role of the serotonin (5-HT) neurochemical system in the treatment and pathophysiology of OCD. However, drug treatment approaches that modify function of interrelated neurochemical systems, such as the dopamine and glutamate systems, are also briefly discussed as they promise to complement and enhance SSRI treatment effects.

Original languageEnglish
Pages (from-to)325-332
Number of pages8
JournalDrug Discovery Today
Volume13
Issue number7-8
DOIs
StatePublished - Apr 2008

Fingerprint

Obsessive-Compulsive Disorder
Serotonin
Therapeutics
Pharmaceutical Preparations
Psychiatry
Glutamic Acid
Dopamine

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. / Goddard, Andrew W.; Shekhar, Anantha; Whiteman, Aaron F.; McDougle, Christopher J.

In: Drug Discovery Today, Vol. 13, No. 7-8, 04.2008, p. 325-332.

Research output: Contribution to journalArticle

Goddard, Andrew W. ; Shekhar, Anantha ; Whiteman, Aaron F. ; McDougle, Christopher J. / Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. In: Drug Discovery Today. 2008 ; Vol. 13, No. 7-8. pp. 325-332.
@article{a2e118721ac34c73bb5f934f900e7183,
title = "Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder",
abstract = "Obsessive-compulsive disorder (OCD) is a disabling psychiatric condition affecting 1-2{\%} of the community. Although modern drug, behavioral and psychosurgical therapies have improved the prognosis of OCD considerably, approximately 30{\%} of patients remain treatment-refractory. Currently, selective serotonin (5-HT) reuptake inhibitors (SSRIs) are the drug treatments of choice for OCD. Accordingly, this review evaluates the evidence for a role of the serotonin (5-HT) neurochemical system in the treatment and pathophysiology of OCD. However, drug treatment approaches that modify function of interrelated neurochemical systems, such as the dopamine and glutamate systems, are also briefly discussed as they promise to complement and enhance SSRI treatment effects.",
author = "Goddard, {Andrew W.} and Anantha Shekhar and Whiteman, {Aaron F.} and McDougle, {Christopher J.}",
year = "2008",
month = "4",
doi = "10.1016/j.drudis.2007.12.009",
language = "English",
volume = "13",
pages = "325--332",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "7-8",

}

TY - JOUR

T1 - Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder

AU - Goddard, Andrew W.

AU - Shekhar, Anantha

AU - Whiteman, Aaron F.

AU - McDougle, Christopher J.

PY - 2008/4

Y1 - 2008/4

N2 - Obsessive-compulsive disorder (OCD) is a disabling psychiatric condition affecting 1-2% of the community. Although modern drug, behavioral and psychosurgical therapies have improved the prognosis of OCD considerably, approximately 30% of patients remain treatment-refractory. Currently, selective serotonin (5-HT) reuptake inhibitors (SSRIs) are the drug treatments of choice for OCD. Accordingly, this review evaluates the evidence for a role of the serotonin (5-HT) neurochemical system in the treatment and pathophysiology of OCD. However, drug treatment approaches that modify function of interrelated neurochemical systems, such as the dopamine and glutamate systems, are also briefly discussed as they promise to complement and enhance SSRI treatment effects.

AB - Obsessive-compulsive disorder (OCD) is a disabling psychiatric condition affecting 1-2% of the community. Although modern drug, behavioral and psychosurgical therapies have improved the prognosis of OCD considerably, approximately 30% of patients remain treatment-refractory. Currently, selective serotonin (5-HT) reuptake inhibitors (SSRIs) are the drug treatments of choice for OCD. Accordingly, this review evaluates the evidence for a role of the serotonin (5-HT) neurochemical system in the treatment and pathophysiology of OCD. However, drug treatment approaches that modify function of interrelated neurochemical systems, such as the dopamine and glutamate systems, are also briefly discussed as they promise to complement and enhance SSRI treatment effects.

UR - http://www.scopus.com/inward/record.url?scp=41549167783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549167783&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2007.12.009

DO - 10.1016/j.drudis.2007.12.009

M3 - Article

C2 - 18405845

AN - SCOPUS:41549167783

VL - 13

SP - 325

EP - 332

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 7-8

ER -